Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abbott Laboratories (ABT) vs The Coca-Cola Co K (KO) Price & Performance

Abbott LaboratoriesTrade
The Coca-Cola Co KTrade

Price performance (Past 24H)

Key statistics

Abbott Laboratories vs The Coca-Cola Co K — how do they compare? Abbott Laboratories trades at $109.01 (market cap $187.95B), while The Coca-Cola Co K trades at $86.3 (market cap $372.08B). The key difference: The Coca-Cola Co K is the larger of the two by market cap, and The Coca-Cola Co K pays the higher dividend (2.45%). Which is the better fit depends on your goals.

ABTKO
Market Cap
$187.95B$372.08B
Sector
HealthConsumer Staples
52-Week High
$136.62$89.08
52-Week Low
$82.57$65.67
Enterprise Value
$214.96B$399.26B
Dividend Yield
2.32%2.45%
Volume
14,630,257

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abbott Laboratories

Abbott Laboratories (ABT) trades at $109.74, up 1.8% on the day, with a bullish technical signal from moving averages and strong analyst consensus. Recent financials show revenue growth to $44.33 billion in 2025, though net income declined to $6.52 billion. Key developments include a CE Mark for dual glucose-ketone sensors, enhancing its diabetes care portfolio. The stock is near its 52-week high, with support at $108 and resistance at $109.

Outlook remains positive with a consensus price target of $120.70, offering ~10% upside. Risks include competitive pressures in medical devices and macroeconomic volatility. Earnings beats in Q1 and Q2 2026 support growth, but margin compression and high P/E of 35.15 warrant caution for value-focused investors.

The Coca-Cola Co K

Coca-Cola (KO) trades at $86.87, down 0.21% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.97 exceeding the $0.92 forecast. Key valuation ratios include a P/E of 26.09 and ROE of 44.23%, while cash flow trends show robust operational performance. Recent news highlights institutional buying and stable demand trends ahead of Q3 earnings.

The outlook remains positive with a consensus price target of $95.83, implying 10.3% upside. Strengths include a 64-year dividend growth streak and high profitability, but risks involve regional demand divergence and elevated debt levels. Analyst sentiment is bullish with 60% buy ratings, supporting a favorable investment case for long-term holders.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Read more on ABT

About The Coca-Cola Co K

The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.

Read more on KO